公开(公告)号：US09090575B2

公开(公告)日：2015-07-28

申请号：US13927678

申请日：2013-06-26

Applicant: H. Lundbeck A/S

Inventor： Thomas Ruhland ,  Garrick P. Smith ,  Benny Bang-Andersen ,  Ask Puschl ,  Ejner K. Moltzen ,  Kim Andersen

IPC: C07D295/096 ,  C07D211/20 ,  C07D211/70 ,  C07D243/08

CPC classification number: C07D295/145 ,  C07D211/20 ,  C07D211/70 ,  C07D243/08 ,  C07D295/033 ,  C07D295/096

Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.

Abstract translation: 本发明提供由通式I表示的化合物，其中取代基在本申请中定义。 这些化合物可用于治疗情感障碍，包括抑郁症，焦虑症，包括一般焦虑症，惊恐障碍和强迫症。

公开(公告)号：US08969355B2

公开(公告)日：2015-03-03

申请号：US14480949

申请日：2014-09-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Andre Faldt ,  Rene Holm ,  Heidi Lopez de Diego

IPC: A61K31/495 ,  C07D295/096 ,  A61K9/14

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

Abstract translation: 本公开涉及治疗选自情感障碍，抑郁症，重度抑郁障碍，焦虑症，一般焦虑症，社会焦虑症，强迫症，惊恐障碍和惊恐发作的疾病的方法。 该方法包括向有需要的患者施用治疗有效量的化合物I或其药学上可接受的盐，其中化合物I是1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪。

公开(公告)号：US10258617B2

公开(公告)日：2019-04-16

申请号：US15890006

申请日：2018-02-06

Applicant: H. Lundbeck A/S

Inventor： Connie Sanchez Morillo ,  Karina Krøjer Søby ,  Benny Bang-Andersen

IPC: A61K31/495 ,  A61K9/00 ,  A61K9/08 ,  A61K47/40

Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.

公开(公告)号：US09913839B2

公开(公告)日：2018-03-13

申请号：US15703572

申请日：2017-09-13

Applicant: H. Lundbeck A/S

Inventor： Connie Sanchez Morillo ,  Karina Krøjer Søby ,  Benny Bang-Andersen

IPC: A61K31/497 ,  A61K31/495 ,  A61K9/08 ,  A61K9/00

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/08 ,  A61K47/40 ,  A61K2300/00

Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.

公开(公告)号：US09708280B2

公开(公告)日：2017-07-18

申请号：US14744197

申请日：2015-06-19

Applicant: H. Lundbeck A/S

Inventor： Thomas Ruhland ,  Garrick Paul Smith ,  Benny Bang-Andersen ,  Ask Puschl ,  Ejner Knud Moltzen ,  Kim Andersen

IPC: C07D295/096 ,  C07D295/145 ,  C07D211/20 ,  C07D211/70 ,  C07D243/08 ,  C07D295/033

CPC classification number: C07D295/145 ,  C07D211/20 ,  C07D211/70 ,  C07D243/08 ,  C07D295/033 ,  C07D295/096

Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.

公开(公告)号：US09315459B2

公开(公告)日：2016-04-19

申请号：US14542210

申请日：2014-11-14

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Andre Faldt ,  Tine Bryan Stensbol ,  Silke Miller ,  Heidi Lopez De Diego

IPC: C07D211/20 ,  C07C55/08 ,  C07C55/12 ,  C07C59/08 ,  C07C229/24

CPC classification number: C07D211/20 ,  C07B2200/13 ,  C07C55/08 ,  C07C55/12 ,  C07C59/08 ,  C07C229/24

Abstract: Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided, e.g., for the treatment of neuropathic pain.

Abstract translation: 提供4- [2-（4-甲基苯基硫基） - 苯基]哌啶及其盐的结晶形式，例如用于治疗神经性疼痛。

公开(公告)号：US20130303770A1

公开(公告)日：2013-11-14

申请号：US13890705

申请日：2011-11-10

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Benny Bang-Andersen

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K51/0455 ,  C07B59/002 ,  G01N33/60

Abstract: The present invention relates to radiolabelled PDE10A ligands which are useful for imaging and quantifying the PDE10A enzyme using positron emission tomography (PET).

Abstract translation: 本发明涉及放射性标记的PDE10A配体，其可用于使用正电子发射断层摄影（PET）成像和定量PDE10A酶。

公开(公告)号：US20130190352A1

公开(公告)日：2013-07-25

申请号：US13660718

申请日：2012-10-25

Applicant: H. LUNDBECK A/S

Inventor： Benny Bang-Andersen ,  Andre Fajdt ,  Tine Bryan Stensbol ,  Silke Miller ,  Heidi Lopez De Diego

IPC: C07D211/20 ,  C07C229/24 ,  C07C59/08 ,  C07C55/08 ,  C07C55/12

CPC classification number: C07D211/20 ,  C07B2200/13 ,  C07C55/08 ,  C07C55/12 ,  C07C59/08 ,  C07C229/24

Abstract: Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided e.g. for the treatment of neuropathic pain.

Abstract translation: 提供4- [2-（4-甲基苯基硫基） - 苯基]哌啶及其盐的结晶形式。 用于治疗神经性疼痛。